Fonte: Oral oncology. Nome do evento: Multidisciplinary Head and Neck Cancers Symposium. Unidade: FM
Assuntos: ANTI-INFLAMATÓRIOS, ANTÍGENOS, LINFÓCITOS T, CITOCINAS, NEOPLASIAS BUCAIS, CARCINOMA DE CÉLULAS ESCAMOSAS
ABNT
WOLF, Gregory T et al. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. Oral oncology, v. 111, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.oraloncology.2020.104928. Acesso em: 09 maio 2024.APA
Wolf, G. T., Liu, S., Bellile, E., Sartor, M., Rozek, L., Thomas, D., et al. (2020). Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial. Oral oncology, 111. doi:10.1016/j.oraloncology.2020.104928NLM
Wolf GT, Liu S, Bellile E, Sartor M, Rozek L, Thomas D, Nguyen A, Zarins K, Mchugh JB, Cernea CR. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial [Internet]. Oral oncology. 2020 ; 111[citado 2024 maio 09 ] Available from: https://doi.org/10.1016/j.oraloncology.2020.104928Vancouver
Wolf GT, Liu S, Bellile E, Sartor M, Rozek L, Thomas D, Nguyen A, Zarins K, Mchugh JB, Cernea CR. Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial [Internet]. Oral oncology. 2020 ; 111[citado 2024 maio 09 ] Available from: https://doi.org/10.1016/j.oraloncology.2020.104928